vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Envela Corp (ELA). Click either name above to swap in a different company.

Envela Corp is the larger business by last-quarter revenue ($80.5M vs $48.0M, roughly 1.7× BICYCLE THERAPEUTICS PLC). Envela Corp runs the higher net margin — 7.4% vs -42.0%, a 49.5% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 66.6%). Envela Corp produced more free cash flow last quarter ($-3.7M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 42.1%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.

BCYC vs ELA — Head-to-Head

Bigger by revenue
ELA
ELA
1.7× larger
ELA
$80.5M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1126.7% gap
BCYC
1193.3%
66.6%
ELA
Higher net margin
ELA
ELA
49.5% more per $
ELA
7.4%
-42.0%
BCYC
More free cash flow
ELA
ELA
$16.2M more FCF
ELA
$-3.7M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
42.1%
ELA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
ELA
ELA
Revenue
$48.0M
$80.5M
Net Profit
$-20.2M
$6.0M
Gross Margin
20.5%
Operating Margin
-51.5%
9.4%
Net Margin
-42.0%
7.4%
Revenue YoY
1193.3%
66.6%
Net Profit YoY
61.1%
274.6%
EPS (diluted)
$-0.29
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
ELA
ELA
Q4 25
$48.0M
$80.5M
Q3 25
$11.7M
$57.4M
Q2 25
$2.9M
$54.9M
Q1 25
$10.0M
$48.3M
Q4 24
$3.7M
$48.3M
Q3 24
$2.7M
$46.9M
Q2 24
$9.4M
$45.3M
Q1 24
$19.5M
$39.9M
Net Profit
BCYC
BCYC
ELA
ELA
Q4 25
$-20.2M
$6.0M
Q3 25
$-59.1M
$3.4M
Q2 25
$-79.0M
$2.8M
Q1 25
$-60.8M
$2.5M
Q4 24
$1.6M
Q3 24
$-50.8M
$1.7M
Q2 24
$-39.8M
$1.6M
Q1 24
$-26.6M
$1.9M
Gross Margin
BCYC
BCYC
ELA
ELA
Q4 25
20.5%
Q3 25
22.8%
Q2 25
22.6%
Q1 25
24.8%
Q4 24
23.1%
Q3 24
24.4%
Q2 24
25.1%
Q1 24
25.9%
Operating Margin
BCYC
BCYC
ELA
ELA
Q4 25
-51.5%
9.4%
Q3 25
-558.6%
7.3%
Q2 25
-2965.8%
5.9%
Q1 25
-703.7%
6.5%
Q4 24
3.9%
Q3 24
-2385.9%
4.3%
Q2 24
-498.3%
4.2%
Q1 24
-162.4%
5.9%
Net Margin
BCYC
BCYC
ELA
ELA
Q4 25
-42.0%
7.4%
Q3 25
-503.7%
5.8%
Q2 25
-2703.8%
5.0%
Q1 25
-608.9%
5.2%
Q4 24
3.3%
Q3 24
-1898.4%
3.6%
Q2 24
-425.3%
3.5%
Q1 24
-136.0%
4.8%
EPS (diluted)
BCYC
BCYC
ELA
ELA
Q4 25
$-0.29
$0.22
Q3 25
$-0.85
$0.13
Q2 25
$-1.14
$0.11
Q1 25
$-0.88
$0.10
Q4 24
$0.07
Q3 24
$-0.74
$0.06
Q2 24
$-0.77
$0.06
Q1 24
$-0.62
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
ELA
ELA
Cash + ST InvestmentsLiquidity on hand
$628.1M
Total DebtLower is stronger
$9.9M
Stockholders' EquityBook value
$610.0M
$67.1M
Total Assets
$717.6M
$96.0M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
ELA
ELA
Q4 25
$628.1M
Q3 25
$648.3M
Q2 25
$721.5M
Q1 25
$793.0M
Q4 24
$879.5M
Q3 24
$890.9M
Q2 24
$961.4M
Q1 24
$457.0M
$19.8M
Total Debt
BCYC
BCYC
ELA
ELA
Q4 25
$9.9M
Q3 25
$12.5M
Q2 25
$13.0M
Q1 25
$13.2M
Q4 24
$13.5M
Q3 24
$13.8M
Q2 24
$30.9M
$14.3M
Q1 24
$30.8M
$14.6M
Stockholders' Equity
BCYC
BCYC
ELA
ELA
Q4 25
$610.0M
$67.1M
Q3 25
$618.5M
$61.1M
Q2 25
$668.9M
$57.8M
Q1 25
$740.3M
$55.1M
Q4 24
$793.1M
$52.7M
Q3 24
$831.0M
$51.1M
Q2 24
$873.8M
$50.2M
Q1 24
$356.0M
$49.3M
Total Assets
BCYC
BCYC
ELA
ELA
Q4 25
$717.6M
$96.0M
Q3 25
$764.0M
$90.9M
Q2 25
$832.2M
$82.7M
Q1 25
$883.9M
$79.7M
Q4 24
$956.9M
$77.9M
Q3 24
$996.7M
$77.4M
Q2 24
$1.1B
$73.8M
Q1 24
$547.1M
$74.7M
Debt / Equity
BCYC
BCYC
ELA
ELA
Q4 25
0.15×
Q3 25
0.20×
Q2 25
0.23×
Q1 25
0.24×
Q4 24
0.26×
Q3 24
0.27×
Q2 24
0.04×
0.29×
Q1 24
0.09×
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
ELA
ELA
Operating Cash FlowLast quarter
$-19.3M
$-3.5M
Free Cash FlowOCF − Capex
$-19.9M
$-3.7M
FCF MarginFCF / Revenue
-41.5%
-4.6%
Capex IntensityCapex / Revenue
1.2%
0.2%
Cash ConversionOCF / Net Profit
-0.59×
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$1.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
ELA
ELA
Q4 25
$-19.3M
$-3.5M
Q3 25
$-71.2M
$2.4M
Q2 25
$-72.8M
$2.6M
Q1 25
$-86.4M
$1.1M
Q4 24
$-164.7M
$3.7M
Q3 24
$-39.8M
$3.4M
Q2 24
$-44.6M
$-789.5K
Q1 24
$-70.9M
$3.8M
Free Cash Flow
BCYC
BCYC
ELA
ELA
Q4 25
$-19.9M
$-3.7M
Q3 25
$-71.8M
$2.2M
Q2 25
$-73.3M
$2.1M
Q1 25
$-87.0M
$746.6K
Q4 24
$-166.0M
$3.2M
Q3 24
$-40.3M
$1.5M
Q2 24
$-45.0M
$-1.3M
Q1 24
$-70.9M
$3.3M
FCF Margin
BCYC
BCYC
ELA
ELA
Q4 25
-41.5%
-4.6%
Q3 25
-612.3%
3.8%
Q2 25
-2509.7%
3.9%
Q1 25
-871.7%
1.5%
Q4 24
-4475.7%
6.7%
Q3 24
-1504.7%
3.1%
Q2 24
-481.2%
-2.9%
Q1 24
-362.9%
8.4%
Capex Intensity
BCYC
BCYC
ELA
ELA
Q4 25
1.2%
0.2%
Q3 25
5.7%
0.4%
Q2 25
17.1%
0.8%
Q1 25
6.1%
0.8%
Q4 24
33.3%
1.0%
Q3 24
16.3%
4.2%
Q2 24
4.5%
1.1%
Q1 24
0.1%
1.1%
Cash Conversion
BCYC
BCYC
ELA
ELA
Q4 25
-0.59×
Q3 25
0.72×
Q2 25
0.94×
Q1 25
0.45×
Q4 24
2.34×
Q3 24
2.05×
Q2 24
-0.50×
Q1 24
1.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

ELA
ELA

Consumer Segment$67.7M84%
Commercial Segment$12.8M16%

Related Comparisons